Stay Informed: Transforming Radiology with Structured Reporting and Data-Driven Approaches

Dive into our activities, projects, and product updates. Catch on the latest industry news and learn who we are as a company and as a team.

Hands holding a glass lung

Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

In a retrospective study conducted at the University Hospital Cologne, the radiological criteria iRECIST and RECIST 1.1 were compared for assessing treatment response in melanoma and NSCLC patients receiving immune checkpoint inhibitors.

The results indicate that iRECIST is better suited for capturing atypical treatment responses to immunotherapies, especially in patients experiencing pseudoprogression. iRECIST could thus contribute to a more accurate evaluation of treatment response and improved immunotherapy outcomes.

Read more about the study here.

Related Resources

Related Resources

University Hospital Jena: Research Investigating the Viability of Accelerating Whole-Body MRI in Children and Adolescents through STIR DWI with Simultaneous Multi-Slice Excitation

This study[1] addressed the challenges of conducting WB-MRI in paediatric patients, particularly the prolonged acquisition time required for…

WUSTL: Discrepant Assessments of Progressive Disease in Clinical Trials between Routine Clinical Reads and Formal RECIST 1.1 Interpretations

In this retrospective study utilizing the mint Lesion™ software[1], researchers found that routine clinical interpretations frequently resulted in the…

A doctor pushes a lying patient into the LDCT device

Early lung cancer detection through LDCT screening as a potential way to improve patient outcomes in Germany

The establishment of a nation-wide lung cancer screening program in Germany has been a subject of considerable interest and debate among healthcare…